Antibiotice takes Ampicillin as far as the US

Iași-based drug maker Antibiotice, a major player in the drug industry, in the first half posted net income worth 17.2m RON (4.2m euros), up almost 15% from a year ago.
At the end of the first half, turnover reached 115.8m RON (27.6m euros), 7.2% more than a year ago.
The turnover trend was largely triggered by exports, which jumped by 35% to around 26m RON (6.3m euros). On the other hand, domestic sales amounted to 89.9m RON, up 1.2%.
As for exports, the company got the necessary licenses from the US Food and Drug Administration to start deliveries of injectable ampicillin to the US. In the first six months, Antibiotice delivered around 300,000 ampoules on this market.
“Over the next three years, Antibiotice wants to develop international projects with eight partners, leading to a major increase in exports,” reads the company’s report.
In 2009, exports generated 18.5% of Antibiotice revenues, but the company plans to reach a 25% weight in the next three years.
In 2010-2012, the company plans to launch 64 prescription drugs and 17 OTCs and nutritional supplements.
“By late 2010, Antibiotice wants to boost turnover by 10% and domestic sales by 18%, retaining the 4th position among Romania’s generics produces, and also to step up exports,” Antibiotice report also reads.